Back to today’s briefing

Story perspectives

New Drug Trials Could Slash Alzheimer's Cases by Millions

5/12/2025

41 10

Summary

Story summary

UVA Health scientists are urging clinical trials for nucleoside reverse transcriptase inhibitors (NRTIs) as a promising strategy to combat Alzheimer’s disease. Their research reveals that NRTIs can lower Alzheimer’s risk by 6% to 13% annually in patients with HIV or hepatitis B, potentially preventing a staggering one million new cases worldwide each year.

1 of 1

Story summary

UVA Health scientists are urging clinical trials for nucleoside reverse transcriptase inhibitors (NRTIs) as a promising strategy to combat Alzheimer’s disease. Their research reveals that NRTIs can lower Alzheimer’s risk by 6% to 13% annually in patients with HIV or hepatitis B, potentially preventing a staggering one million new cases worldwide each year.